Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-3-10
pubmed:abstractText
Immunological phenotyping of acute leukemia have provided enormous and important information for the classification and lineage determination of leukemia. Forty-nine patients with CD7(+) CD56(+) acute myeloid leukemia (AML) were analyzed. There were 17 patients of M0, which corresponded to myeloid/NK cell precursor acute leukemia, and 32 patients of AML other than M0 (9 each for M1 and M2, one for M3, 3 for M4, 4 for M5 and 6 for M7). Age distribution was similar between these two groups, but CD7(+) CD56(+) M0 showed significant male predominance than CD7(+) CD56(+) M1-M7 (M:F = 15:2 vs. 15:17, P = 0.006). The disease localization and the hematological manifestations were different, showing fewer white blood cell counts and circulating leukemic blasts, less anemia, less thrombocytopenia and more frequent extramedullary involvement in M0 group. The prognosis was poor in both groups, and there was no statistical difference. These findings suggest that extramedullary involvement of myeloid/NK cell precursor acute leukemia is not directly derived from the presence of CD7 and CD56 antigens on leukemic cells. The poor prognosis of CD7(+) CD56(+) M1-M7 suggests that this phenotype may act as a prognostic factor for AML, but this should be confirmed in further studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1865-3774
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
303-9
pubmed:meshHeading
pubmed-meshheading:20111912-Adolescent, pubmed-meshheading:20111912-Adult, pubmed-meshheading:20111912-Aged, pubmed-meshheading:20111912-Antigens, CD56, pubmed-meshheading:20111912-Antigens, CD7, pubmed-meshheading:20111912-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20111912-Cyclophosphamide, pubmed-meshheading:20111912-Data Collection, pubmed-meshheading:20111912-Disease-Free Survival, pubmed-meshheading:20111912-Doxorubicin, pubmed-meshheading:20111912-Female, pubmed-meshheading:20111912-Flow Cytometry, pubmed-meshheading:20111912-Humans, pubmed-meshheading:20111912-Immunophenotyping, pubmed-meshheading:20111912-Leukemia, Myeloid, Acute, pubmed-meshheading:20111912-Leukocyte Count, pubmed-meshheading:20111912-Male, pubmed-meshheading:20111912-Middle Aged, pubmed-meshheading:20111912-Prednisone, pubmed-meshheading:20111912-Prognosis, pubmed-meshheading:20111912-Remission Induction, pubmed-meshheading:20111912-Sex Distribution, pubmed-meshheading:20111912-Survival Analysis, pubmed-meshheading:20111912-Tumor Markers, Biological, pubmed-meshheading:20111912-Vincristine, pubmed-meshheading:20111912-Young Adult
pubmed:year
2010
pubmed:articleTitle
The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.
pubmed:affiliation
Department of HSCT Data Management, Nagoya University School of Medicine, 1-1-20 Daiko-minami, Higashi-ku, Nagoya 461-0047, Japan. r-suzuki@med.nagoya-u.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't